Fulgent Genetics, Inc. (FLGT) Stock Price & Analysis
Fulgent Genetics, Inc. (FLGT) fell 1.55% to USD 19.67 as of July 25, 2026 at 03:04 UTC, according to Nexqual real-time market data.
FLGT last closed at USD 19.98; the session ranged USD 19.58–20.06 on volume of 140,225 shares. Market capitalization is $558.64M, with a 52-week range of USD 13.46–31.04 (NGM). Source: Nexqual, July 25, 2026 at 03:04 UTC.
Key Statistics (as of July 25, 2026 at 03:04 UTC)
| Price | USD 19.67 |
|---|---|
| Change | ▼ 1.55% (down) |
| Previous Close | USD 19.98 |
| Open | USD 19.98 |
| Day Range | USD 19.58 – 20.06 |
| 52-Week Range | USD 13.46 – 31.04 |
| Volume | 140,225 shares |
| Market Cap | $558.64M |
| Exchange | NGM |
Technical Analysis (FLGT)
Nexqual's technical model rates FLGT "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 03:04 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 46.2 (neutral) |
| vs SMA50 | Above (USD 18.89) |
| MACD | 0.25 (positive) |
Analyst Ratings (FLGT)
Wall Street analysts rate FLGT "None" based on 2 analysts, with a mean price target of USD 18.5 (range USD 15–22), per Nexqual as of July 25, 2026 at 03:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 18.5 |
| High Target | USD 22 |
| Low Target | USD 15 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (FLGT)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.44 |
| Revenue Estimate | $91.77M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.36 vs est -0.35 ▼ miss |
| 2025-12-31 | USD 0.16 vs est 0.03 ▲ beat |
| 2025-09-30 | USD 0.14 vs est -0.22 ▲ beat |
| 2025-06-30 | USD 0.07 vs est -0.18 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financials & Fundamentals (FLGT)
| Total Revenue | $320.35M |
|---|---|
| Revenue Growth (YoY) | -3.20% |
| Gross Margin | +38.71% |
| Operating Margin | -45.01% |
| Profit Margin | -23.04% |
| ROE | -6.92% |
| Debt / Equity | 0.97 |
| Current Ratio | 5.32 |
| Total Cash | $276.30M |
| Total Debt | $10.17M |
| Free Cash Flow | $-105.94M |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financial Health Score (FLGT)
Nexqual rates Fulgent Genetics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:04 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 39%, operating -45% |
| Balance Sheet | Strong — $276M cash vs $10M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$106M, burning cash |
| Efficiency | Critical — ROE -7%, ROA -5.4% |
Ownership (FLGT)
| Insider Ownership | +36.66% |
|---|---|
| Institutional Ownership | +63.41% |
| Shares Outstanding | 28.40M |
| Float | 17.56M |
| Short % of Float | +14.58% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Leadership (FLGT)
Fulgent Genetics, Inc. is led by Ming Hsieh (age 69), Chairman & CEO, per Nexqual as of July 25, 2026 at 03:04 UTC.
| Chairman & CEO | Ming Hsieh (age 69) |
|---|---|
| COO & President | Jian Xie (age 59) |
| Chief Financial Officer | Paul Kim (age 58) |
| Chief Scientific Officer & Lab Director | Hanlin Gao D.A.B.M.G., FACMG (age 58) |
| Vice President of Operations & Compliance | Doreen Ng |
Major Backers & Investors (FLGT)
Notable institutional backers of Fulgent Genetics, Inc. include RTW Investments LP, Acadian Asset Management. LLC, Invenomic Capital Management, LP, according to Nexqual as of July 25, 2026 at 03:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 4.54% |
| Acadian Asset Management. LLC | 4.34% |
| Invenomic Capital Management, LP | 2.15% |
| Ameriprise Financial, Inc. | 1.98% |
| Shaw D.E. & Co., Inc. | 1.71% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 13.8% |
| Vanguard Group | 6.12% |
| Dimensional Fund Advisors | 2.36% |
| Geode Capital | 2.06% |
| State Street | 1.86% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
From Fulgent Genetics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Picture tests help individuals identify important health markers to empower their personal health journey. 1   Our Laboratory Services Technology Platform Our proprietary technology platform for our laboratory services business includes proprietary gene probes, data suppression and comparison algorithms, AI learning software, and proprietary laboratory information management systems.
- We seek to protect our proprietary technology and processes, and obtain and maintain ownership of certain technologies, in part, through non-disclosure and intellectual property assignment agreements with our employees, consultants, and commercial partners.
- We also seek to preserve the integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical and electronic security of our information technology systems.
- This acquisition enables us to secure full ownership of the patents we previously licensed from ANP to develop, strengthen, and maintain our proprietary position in the fields targeted by our product candidates, including FID-007 and FID-022, which are currently in clinical studies.
Partnerships
- Previously, in June 2017, we entered into an exclusive license agreement with ANP Technologies, Inc., or ANP, as amended on December 28, 2017, and May 1, 2024.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| APPN | Appian Corporation | USD 23.75 | ▲ 4.9% |
| FVRR | Fiverr International Ltd. | USD 10.46 | ▼ 0.38% |
| MGNI | Magnite, Inc. | USD 18.51 | ▲ 1.15% |
| KNSL | Kinsale Capital Group, Inc. | USD 349.1 | ▲ 7.2% |
| WD | Walker & Dunlop, Inc | USD 48.2 | ▲ 0.98% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:04 UTC. This page is informational and not investment advice.